APHINITY | European Journal of Cancer

APHINITY | European Journal of Cancer

OVERVIEW Nearly half of patients in the APHINITY trial were overweight/obese. Overweight/obesity was associated with poorer survival outcomes. Higher chemotherapy discontinuation rates were found in patients with overweight/obesity. Obesity remained linked to poorer...
Cardiac Safety in the APHINITY trial

Cardiac Safety in the APHINITY trial

OVERVIEW ESMO Open has published an article co-authored by a member of our Biostatistics team. Results of the exploratory analysis conclude that after >6 years of median follow-up, pertuzumab and trastuzumab did not increase cardiotoxicity risk compared to...
APHINITY

APHINITY

APHINITY is a large, randomised phase III, double-blind, placebo-controlled study that compares the efficacy and safety of chemotherapy plus trastuzumab and placebo with that of chemotherapy plus trastuzumab and pertuzumab as adjuvant therapy in approximately 4800...